0001193125-26-162774
SEC filingGigCapital7 Corp. amended its business combination agreement with Hadron Energy to reduce the pro-forma equity valuation from $1.2 billion to $600 million and extended the outside closing date from April 30, 2026 to May 31, 2026, while also issuing a $293,000 unsecured convertible promissory note to its sponsor.
The revision of the Business Combination Agreement represents a material recalibration of the transaction economics between GigCapital7 and Hadron Energy, driven explicitly by current public market conditions in the advanced nuclear sector — as stated in Exhibit 99.1, which notes a 'meaningful valuation recalibration since the market peak in Q4 2025' and cites declining equity values among publicly traded peers. The $600 million pro-forma valuation — down 50% from the original $1.2 billion — is not attributed to deterioration in Hadron’s fundamentals but rather to 'disciplined market alignment and investor responsiveness', with management emphasizing credibility and long-term strength over optics. This adjustment serves three investor-critical objectives: reducing redemption risk to preserve cash at close, attracting quality institutional capital for the public float, and establishing a supported aftermarket. The 31-day extension of the Outside Date to May 31, 2026 aligns with the May 7, 2026 extraordinary general meeting, allowing time for shareholder voting and satisfaction of remaining customary closing conditions, including Nasdaq listing requirements. Concurrently, the $293,000 sponsor note — an increase from the prior $148,000 note — provides near-term working capital without dilution or interest burden, and its convertibility into units at $10.00 per unit preserves alignment with the IPO structure. The effectiveness of the Form S-4 on April 15, 2026 confirms regulatory clearance and marks the transition into the final phase of the deSPAC process, where execution discipline and transparent communication — evidenced by the joint press release, updated investor presentation, and proxy supplement — are now central to maintaining investor confidence ahead of closing.